Stock Market Cafe
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Stock Market Cafe
No Result
View All Result
Home Trading News

Novavax Stock Could Hit $315, Says Analyst

by
January 6, 2022
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Novavax (NVAX) shares have been volatile recently. News the EUA filing with the FDA for its Covid-19 vaccine NVX-CoV2373 has been further delayed – the company only submitted data concerning the manufacturing processes, suggesting the EUA filing is still a way off – has not helped matters.

However, B. Riley analyst Mayank Mamtani notes that the fact the final data package has been submitted and it includes Serum Institute of India (SII) generated CMC data that only recently formed the backbone for the WHO and EMA approvals – de-risks the EUA.

RELATED POSTS

Germany’s much-vaunted trade surplus disappears as import prices surge

Yum Brands says it is close to selling its Russian KFC business

Throw in the EUA granted in India and the analyst believes investors have a “compelling opportunity to accumulate additional shares or build a fresh position as the investor expectation resets on the critical role NVX-CoV2373 has to play in ‘endemicizing’ the pandemic globally.”

The sales opportunity for Novavax in the US and the EU is “core” to the long-term thesis, but Mamtani thinks this might be getting overlooked by a couple of “unwarranted” concerns. One which perceives the easily transmissible yet relatively tame omicron variant serving as a “universal, no-consent booster.” The second is due to Novavax’s “continued execution-related challenges.” This mostly pertains to the delays in “CMC data generation activities” in more than 10 North America and EU facilities.

The latter has especially sowed doubt regarding Novavax’ competitiveness compared to available vaccines, as highlighted in a recent Politico article which said Biden administration officials were worried Novavax would be unable to manufacture enough vaccine doses.

Mamtani, however, seems unperturbed by these concerns. “We remind investors of NVAX nearing monthly manufacturing target of 150M doses; primarily via SII with India government permits already secured to export 100M+ doses with most recent permit specific to higher income countries, Netherlands, Australia & NZ where SII’s role is limited to that of a CDMO; implying 70%+ margins, off of a premium-priced product, flowing into NVAX’s profitability as we project ‘2373 to capture meaningful share of the still expanding market, likely to exceed $60B in 2022,” the analyst duly explained.

With all this as backdrop, Mamtani thinks a new price target is in order; the figure rises from $305 to a new Street-high of $315, suggesting shares will climb by 120% over the next 12 months. The analyst’s rating stays a Buy. (To watch Mamtani’s track record, click here)

While the Street’s average target is a more conservative $268, that figure can still generate returns of 87% in the year ahead. Overall, the stock has a Strong Buy consensus rating, based on 4 Buys vs. 1 Hold. (See Novavax stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

ShareTweetPin

Related Posts

Germany’s much-vaunted trade surplus disappears as import prices surge

by
July 5, 2022
0

Germany trade entered negative territory in May, raising questions about the stability of its economy in the wake of Russia's...

Yum Brands says it is close to selling its Russian KFC business

by
July 5, 2022
0

In this article YUM A woman walks near closed KFC and McDonald's restaurants that suspended their business in Russia due...

Dow falls 700 points as Wall Street grapples with recession concerns

by
July 5, 2022
0

Traders on the floor of the NYSE, July 1, 2022. Source: NYSE Stock futures were lower early on Tuesday morning...

Seeking at Least 11% Dividend Yield? Analysts Suggest 2 Dividend Stocks to Buy

by
July 5, 2022
0

Insider Monkey 10 Best Bargain Stocks To Buy Right Now In this article, we discuss 10 best bargain stocks to...

Borrowers are on edge—will Biden cancel student debt or not? Here’s what’s going on.

by
July 5, 2022
0

This article is reprinted by permission from NerdWallet.  The “will he, won’t he” summer of student debt cancellation is upon us. The...

Next Post

European markets set to drop sharply at the open following U.S. sell-off

Global markets slump on hawkish Fed minutes; tech rout spills into Europe

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Crocs sees fourth-quarter sales up 42%, CEO Andrew Rees says 2021 was ‘exceptional year’

    0 shares
    Share 0 Tweet 0
  • Buying a car from the factory sounds expensive, but it can actually save you money. Here’s how to do it.

    0 shares
    Share 0 Tweet 0
  • Roth TSP vs. Roth IRA: How Do They Compare?

    0 shares
    Share 0 Tweet 0
  • The states that won’t tax military retirement in 2022

    0 shares
    Share 0 Tweet 0
  • Allbirds stock has plunged 50% in two months, now one top analyst says buy it

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.stockmarket-cafe.com
No Result
View All Result
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.stockmarket-cafe.com